30-day average of 23 articles · scale −100 to +100
Across 23 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Moderna news is Somewhat Bullish (+31)
on a scale from −100 to +100.
That is about the same as the previous 30 days (+33).
📈 Moderna raised 2026 revenue growth outlook to 15-25% driven by international performance.
⚠️ Cash outflow reached $1.56B due to litigation settlement and working capital swings.
Slightly Bullish +25
The Single Most Important Metric For Moderna Stock
AI-generated analysis
Key insights
📈 Moderna raised its 2026 total revenue growth outlook to 15% to 25%, up from a previous expectation of up to 10%, driven by strong international performance.
🌍 International revenue reached $900 million in the first nine months of 2026, exceeding the company's full-year 2025 total and representing about 40% of Q3 sales.
💰 The company reported an operating profit of $0.13 billion in Q3 2026, a turnaround from a $0.26 billion loss in the same quarter last year.
📉 Cash flow remains negative with a $1.56 billion outflow in Q3 due to a $950 million litigation settlement payment and seasonal working capital swings.
🏥 U.S. domestic COVID-19 vaccination momentum is trending flat year over year through late October, potentially limiting domestic revenue growth.
💵 Moderna ended the quarter with $8 billion in cash and investments, supported by $2.6 billion in net proceeds from a convertible note issuance.
⚠️ Investors are concerned about Q4 seasonality which may reduce revenue as shipments between quarters shift, potentially offsetting recent third-quarter strength.
📅 Earnings for the full year 2026 are expected to be reported in February 2027, with a focus on whether overseas growth can sustain the raised guidance.
📉 The stock declined 7% during an Analyst Day session on November 12, indicating market skepticism regarding the company's current valuation relative to its financial losses.
📈 Bullish signals
📈Management raised its 2026 revenue growth outlook to 15% to 25%, driven by durable international partnerships in the U.K., Canada, and Australia.
🌍International revenue reached $900 million in the first nine months of 2026, surpassing the company's entire 2025 total sales.
💰The company achieved an operating profit of $0.13 billion in Q3 2026, marking a significant turnaround from a $0.26 billion loss in the same quarter last year.
💵Moderna secured $8 billion in cash and investments at quarter-end, bolstered by $2.6 billion in net proceeds from a convertible note to fund operations.
📉 Risk factors
💰The company reported a twelve-month operating loss of $2.93 billion, which includes a significant $900 million litigation settlement charge.
📉Cash flow from operations was an outflow of $1.56 billion in Q3 2026 due to the large litigation payment and seasonal working capital swings.
🏥U.S. domestic COVID-19 vaccination momentum is trending flat year over year, limiting potential revenue growth in the home market.
⚠️Revenue seasonality poses a risk as Q4 shipments may be lower than Q3, potentially offsetting recent third-quarter strength and impacting full-year guidance.
Article
Moderna (MRNA) is facing a valuation contradiction where its stock trades at 36.8 times sales despite reporting a $2.93 billion operating loss over the last twelve months, which includes a $900 million litigation settlement charge. The company's primary growth driver has shifted to international markets, with revenue outside the U.S. reaching $900 million in the first nine months of 2026, surpassing its entire 2025 total.
Management raised its full-year 2026 revenue growth outlook to between 15% and 25%, citing durable overseas partnerships in the U.K., Canada, and Australia. While international sales now account for approximately 40% of third-quarter revenue, domestic COVID-19 vaccination momentum in the U.S. retail and long-term care channels is trending flat year over year through late October.
Financial performance remains mixed with a shift from loss to profit; Moderna recorded an operating profit of $0.13 billion in the third quarter of 2026 compared to a $0.26 billion loss a year prior, though it still posted a twelve-month operating loss on $2.52 billion in revenue. Cash flow challenges persist with an outflow of $1.56 billion from operations in Q3 due to working capital swings and the litigation payment, although the company holds $8 billion in cash and investments bolstered by recent convertible note proceeds.
Analysts are closely watching Q4 results for potential seasonality adjustments that could offset Q3 strength, with earnings expected in February 2027. The stock fell 7% following an Analyst Day on November 12, reflecting investor caution regarding the sustainability of overseas growth and the company's transition from a pandemic-focused entity to a diversified biopharma player.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
D.A. Davidson & CO. reduced its position in Moderna, Inc. (NASDAQ: MRNA) by 33.7% during the first quarter, selling 28,170 shares to hold a remaining stake of 55,397 shares valued at $2.814 million. This filing highlights a mixed institutional landscape where other major funds like Capital World Investors and Norges Bank established new stakes in the fourth quarter, while Dimensional Fund Advisors significantly increased its holdings by over 123%.
Moderna's stock currently trades with a market capitalization of $24.53 billion and a negative P/E ratio of -7.59, reflecting its biotechnology sector status. The company maintains strong liquidity metrics with a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Recent insider activity includes President Stephen Hoge selling approximately $2.74 million in shares and Director Abbas Hussain reducing his position by over 32%, though total corporate insider ownership remains at 10.80%.
Analyst sentiment regarding MRNA is currently mixed, with a consensus target price of $38.27 from MarketBeat data. While Royal Bank of Canada and Piper Sandler raised their price targets to $45 and $77 respectively with positive or overweight ratings, Goldman Sachs and Bank of America maintain neutral to underperform ratings. The average analyst rating is 'Reduce', indicating a cautious outlook despite the company's established mRNA platform for vaccines and therapeutics.
📉 D.A. Davidson cut holdings by 33.7% to $2.814 million value.
📈 Capital World and Norges Bank added $378M and $79.7M stakes.
💼 President Hoge sold 53,336 shares for $2.74 million in June.
⚖️ Insider sales totalled 125,088 shares worth $6.19 million recently.
🎯 Consensus target is $38.27 with an average 'Reduce' rating.
📉 D.A. Davidson & CO. decreased its Moderna holdings by 33.7% in Q1, selling 28,170 shares to retain a position worth $2.814 million.
📈 Capital World Investors and Norges Bank established new stakes in the fourth quarter valued at approximately $378 million and $79.7 million respectively.
📊 Moderna trades with a market cap of $24.53 billion, a quick ratio of 2.35, and a negative P/E ratio of -7.59.
💼 President Stephen Hoge sold 53,336 shares for $2.74 million under a pre-arranged Rule 10b5-1 trading plan on June 15th.
📉 Director Abbas Hussain reduced his ownership by 32.01% following the sale of 5,682 shares valued at $264,951.
🏦 Corporate insiders have collectively sold 125,088 shares worth $6.19 million over the last ninety days.
📊 Royal Bank of Canada raised its price target to $45.00 with a 'sector perform' rating on July 7th.
📈 Piper Sandler increased its objective to $77.00 and assigned an 'overweight' rating in late June.
⚖️ Goldman Sachs lifted its target price to $49.00 but maintains a 'neutral' stance as of early May.
📉 Bank of America raised its target to $38.00 while assigning an 'underperform' rating on July 7th.
🎯 The consensus analyst target price stands at $38.27 with an average rating of 'Reduce' across twelve analysts.
💊 Moderna specializes in mRNA therapeutics and vaccines, leveraging synthetic mRNA to produce proteins for disease prevention.
Bullish Signals
Capital World Investors added $378.3M stake in Q4.
Norges Bank bought $79.7M position in Q4.
Invesco increased Moderna stake by 15.7% to $212.2M.
Dimensional Fund Advisors raised holdings by 123.2% in Q4.
Royal Bank of Canada set price target at $45.00.
Piper Sandler raised objective to $77.00 with overweight rating.
Moderna liquidity strong with quick ratio of 2.35.
Risk Factors
DA Davidson cut holdings by 33.7% in Q1.
Consensus target $38.27 is below recent price $61.82.
Average analyst rating is 'Reduce'.
President Hoge sold 53,336 shares (3.47% decrease).
Insiders sold 125,088 shares worth $6.19 million.
Bullish Signals
Capital World Investors initiated a new stake worth approximately $378.3 million in the fourth quarter.
Norges Bank purchased a new position valued at roughly $79.7 million during the fourth quarter.
Invesco Ltd. increased its Moderna stake by 15.7% in the third quarter, now holding shares worth $212.2 million.
Dimensional Fund Advisors LP raised its holdings by 123.2% in the fourth quarter, adding nearly 987,000 shares.
Royal Bank of Canada upgraded its price target to $45.00 with a 'sector perform' rating.
Piper Sandler increased its price objective to $77.00 and assigned an 'overweight' rating.
Moderna maintains strong liquidity with a quick ratio of 2.35 and a current ratio of 2.41.
Risk Factors
D.A. Davidson & CO. significantly reduced its holdings by 33.7% in the first quarter.
The consensus analyst target price is $38.27, which is below the recent trading price of $61.82.
The average analyst rating is 'Reduce' based on data from MarketBeat.com.
President Stephen Hoge sold 53,336 shares representing a 3.47% decrease in his personal position.
Director Abbas Hussain reduced his ownership by 32.01% following the sale of 5,682 shares.
Corporate insiders have sold a total of 125,088 shares valued at $6.19 million in the last ninety days.
Goldman Sachs maintains a 'neutral' rating despite raising its price target to $49.00.
Bank of America assigned an 'underperform' rating even after lifting its price objective to $38.00.
Moderna, Inc. (MRNA) is ranked 9th on a list of worst-performing stocks to buy on the dip, according to an analysis published on October 1, 2024. The article contextualizes this ranking within a broader market environment characterized by volatility in late 2024, driven by Federal Reserve rate cut expectations and a rotation away from technology sectors toward real estate and utilities.
The company faces significant near-term headwinds, including declining COVID-19 vaccination rates and delayed revenue ramp-up for its RSV vaccine. Consequently, Moderna plans to reduce its Research and Development budget by approximately 20% over the next three years, discontinuing five programs to cut $1.1 billion from its annual spend by 2027. The company also provides limited sales guidance for 2025 and targets a return to profitability in 2028.
Despite these challenges, Wall Street analysts remain optimistic about Moderna's long-term prospects, citing positive Phase III results for a flu/COVID-19 combo vaccine and recent strategic alliances with BARDA and Mitsubishi Tanabe Pharma. The company expects Q3 2024 sales to increase by 40%–50%, aims to end the year with roughly $9 billion in cash, and has an average analyst target price of $104.53.
📉 Moderna ranks 9th on worst-performing stocks list as of Sept 27.
💰 Company cuts R&D budget by ~20%, reducing annual spend to $1.1B by 2027.
🔬 Three new products, including next-gen COVID and adult RSV vaccines, expected for approval this year.
📈 Q3 2024 sales projected to rise 40%–50% compared to the prior year.
💵 Moderna targets ~$9 billion cash reserves by end of 2024.
📉 Moderna ranks 9th on a list of worst-performing stocks to buy on the dip as of September 27.
📅 The article was published on October 1, 2024, amidst market volatility driven by Federal Reserve rate cut expectations.
💰 Moderna plans to reduce its R&D budget by ~20% over three years, cutting $1.1 billion from annual spend by 2027.
📉 The company faces headwinds from declining COVID-19 vaccination rates and delayed RSV vaccine revenue ramp-up.
🔬 Moderna expects to file for approval of three new products this year, including a next-gen COVID vaccine and an RSV vaccine for adults aged 18–59.
🤝 Recent strategic alliances were announced with BARDA and Mitsubishi Tanabe Pharma to aid product roll-outs.
📈 The company expects Q3 2024 sales to increase by 40%–50% compared to the prior year.
💵 Moderna targets ending 2024 with approximately $9 billion in cash reserves.
🎯 Wall Street analysts have set an average target price of $104.53 for MRNA shares.
⏳ The company plans to achieve operational break-even by 2028 despite providing only light guidance for 2025.
Bullish Signals
Q3 2024 sales expected up 40%–50%.
EMA gave positive opinion on RSV vaccine mRESVIA.
Phase III flu/COVID combo vaccine results positive.
Alliances with BARDA and Mitsubishi aid roll-outs.
$9 billion cash by end of 2024.
Risk Factors
R&D budget cuts ~20% due to low sales projections.
Discontinuing programs slashes $1.1B from annual R&D budget.
Apollon Wealth Management LLC purchased 6,842 shares of Moderna (MRNA) in the first quarter, valued at approximately $348,000. Other institutional investors including MUFG Securities EMEA plc and Flagship Harbor Advisors LLC also added new positions worth roughly $28,000 and $31,000 respectively in the second and fourth quarters. Smaller funds like Ameriflex Group Inc. and Cromwell Holdings LLC significantly increased their holdings by over 3,700% and 39.7% respectively, though their total share counts remain relatively low compared to major institutions.
Insider trading activity saw significant sales from company leadership. Director Abbas Hussain sold 5,682 shares for approximately $264,951 in a pre-arranged Rule 10b5-1 plan on May 1st. President Stephen Hoge executed a larger sale of 53,336 shares worth about $2.74 million on June 15th under a similar trading plan. Collectively, insiders sold over 125,000 shares valued at more than $6.19 million during the last quarter, leaving them with 10.80% ownership of the company.
Moderna reported its latest earnings on May 1st, posting revenue of $389 million which beat analyst estimates of $236.37 million by a wide margin, representing a 260.2% year-over-year increase. However, the company reported an EPS loss of $3.40 per share, missing the consensus estimate of a smaller loss of $3.02. The stock currently trades at a market cap of $32.46 billion with a price-to-earnings ratio of -10.04, reflecting its unprofitable status despite strong revenue growth.
The article provides detailed financial metrics including a current ratio of 2.41 and a debt-to-equity ratio of 0.08, indicating a strong balance sheet with minimal debt. Analysts forecast an EPS of -6.51 for the current year. Moderna specializes in mRNA therapeutics and vaccines, with its flagship product being the COVID-19 vaccine which received full approval in multiple jurisdictions. The stock has seen significant volatility, trading between a one-year low of $22.28 and a high of $85.60.
📈 Apollon Wealth acquired 6,842 shares valued at $348,000 in Q1.
📉 President Hoge sold 53,336 shares worth $2.74 million on June 15.
💰 Moderna revenue hit $389M, beating estimates of $236.37M.
Moderna (MRNA) shares surged to a 52-week peak of $81.42 on July 6, marking a 169% annual gain and pushing the market cap to approximately $32.2 billion. This rally was driven by renewed enthusiasm for mRNA technology, including FDA advisory panel endorsement for its seasonal influenza vaccine (mRNA-1010) for adults over 50, and progress on its in vivo CAR-T initiative targeting autoimmune conditions.
Despite the stock price momentum, Wall Street analysts maintain a cautious stance with an average 'Reduce' rating and a consensus price target of $37.13, significantly below current trading levels. Goldman Sachs raised its projection to $49 while maintaining a neutral stance, whereas Bank of America and Barclays adjusted targets upward but kept underperform or equal weight ratings respectively.
Financial performance in Q1 showed mixed results with revenue surging 260% year-over-year to $389 million, beating estimates, though EPS missed at -$3.40 versus a forecast of -$3.02. While institutional investors like Louisiana State Employees Retirement System expanded holdings, corporate insiders collectively sold over 125,000 shares worth more than $6.1 million in the last 90 days.
📈 Stock hit $81.42 high with 169% annual return.
💰 Q1 revenue surged 260% to $389 million.
🏥 FDA panel unanimously endorsed flu vaccine for seniors.
🧬 mRNA-6007 CAR-T therapy advanced into preliminary development.
📉 Analysts maintain 'Reduce' rating with $37.13 price target.
📈 Moderna stock hit a 52-week high of $81.42 on July 6, representing a 169% total return over the past year.
🏥 The FDA advisory panel unanimously endorsed Moderna's experimental seasonal flu vaccine (mRNA-1010) for individuals aged 50 and older.
🧬 mRNA-6007, an in vivo CAR-T therapy for autoimmune diseases like systemic lupus erythematosus, advanced into preliminary development.
💰 Q1 revenue jumped 260% year-over-year to $389 million, significantly exceeding the analyst estimate of $236.37 million.
📉 Analyst consensus remains 'Reduce' with a mean price target of $37.13, less than half of the current trading price.
🏦 Goldman Sachs raised its price target to $49 while maintaining a neutral rating on the stock.
📉 Corporate insiders sold 125,088 shares totaling over $6.1 million during the previous 90-day period.
🏛️ Board member Noubar Afeyan reduced his position by 70.24% by selling 9,263 shares on May 21.
📊 Institutional ownership stands at 75.33%, with Louisiana State Employees Retirement System establishing a new position of 17,700 shares.
📉 Moderna reported Q1 earnings per share of -$3.40, missing the consensus forecast of -$3.02.
Bullish Signals
Stock hit 52-week peak of $81.42 with 169% annual gain.
Q1 revenue surged 260.2% to $389 million, beating estimates.
FDA panel unanimously endorsed seasonal flu vaccine for ages 50+.
mRNA-6007 CAR-T initiative advancing into preliminary autoimmune development.
Analysts target $37.13, under 50% of current price.
Insiders sold 125,088 shares worth over $6.1 million.
Q1 EPS hit -$3.40, missing the -$3.02 forecast.
Equity ranks as most overextended per InvestingPro analytics.
Bullish Signals
Moderna stock reached a fresh 52-week peak of $81.42, delivering a remarkable 169% annual increase and a 124% climb over six months.
Q1 revenue surged 260.2% year-over-year to $389 million, significantly beating the analyst estimate of $236.37 million.
The FDA advisory panel delivered a unanimous endorsement for Moderna's experimental seasonal influenza vaccine (mRNA-1010) for the 50-and-over demographic.
Moderna disclosed that its mRNA-6007 in vivo CAR-T initiative is advancing into preliminary development targeting autoimmune conditions like systemic lupus erythematosus.
Institutional investors are accumulating shares, with Louisiana State Employees Retirement System establishing a fresh position of 17,700 shares valued at approximately $899,000.
Risk Factors
Wall Street analysts hold an average 'Reduce' stance with a consensus price objective of $37.13, representing less than 50% of current trading levels.
Corporate insiders have offloaded 125,088 shares totaling more than $6.1 million over the previous 90 days, indicating potential lack of confidence at current valuations.
Q1 earnings per share registered at -$3.40, falling short of the consensus forecast of -$3.02 despite strong revenue growth.
InvestingPro analytics position the equity among the platform's most overextended securities when measured against its Fair Value assessment.
Moderna (MRNA) shares surged 14% to $68 in Friday afternoon trading, reaching a new 52-week high of $69.29. The rally significantly outpaced peers Merck (MRK), which rose 2%, and Pfizer (PFE), which gained 2%. Analysts attribute the move to momentum from a recent FDA advisory committee vote endorsing Moderna's flu vaccine, mFlusiva, for adults 50 and older, alongside bullish pipeline messaging regarding oncology and autoimmune diseases.
Fundamentally, Moderna reported strong Q1 2026 revenue of $389 million, representing a 264% year-over-year increase that beat consensus estimates by 65%. The company reaffirmed guidance for up to 10% revenue growth in 2026. However, the stock trades at a forward P/E ratio of 23x on uncertain earnings, with a consensus analyst price target of $43.45, well below current levels. Insider transactions have recently tilted toward selling, suggesting investors should maintain modest position sizes given the stock's volatility.
Looking ahead, the next major catalyst is the August 5, 2026 FDA decision on mRNA-1010, which would mark Moderna's fifth approved product if cleared by the PDUFA date. Investors are also monitoring upcoming Phase 3 readouts for norovirus, intismeran in melanoma, and propionic acidemia. While the stock has gained 45% over the past month against Merck's 7% gain and Pfizer's decline, the sell-side consensus remains cautious with multiple Hold ratings.
📈 Moderna shares hit new 52-week high of $69.29.
💰 Q1 revenue surged 264% to $389 million, beating estimates.
🏥 FDA unanimously endorsed flu vaccine mFlusiva for adults 50+.
⏳ August 5, 2026 FDA decision on mRNA-1010 is key.
🎯 Company targets 2028 break-even while expanding oncology therapies.
📈 Moderna shares jumped 14% to $68, hitting a new 52-week high of $69.29 in Friday afternoon trading.
🏥 The FDA advisory committee unanimously endorsed Moderna's flu vaccine mFlusiva for adults 50 and older.
💰 Q1 2026 revenue reached $389 million, a 264% year-over-year increase that beat consensus by 65%.
📅 The company reaffirmed guidance for up to 10% revenue growth in 2026 in its latest 10-Q filing.
🎯 Moderna aims for a 2028 break-even goal while expanding into oncology and autoimmune disease therapies.
📉 Pfizer's Comirnaty revenue fell 59% to $232 million, highlighting reliance on non-COVID portfolios.
📊 Moderna stock is up 45% over the past month compared to Merck's 7% gain and Pfizer's 6% loss.
💸 The consensus analyst price target sits at $43.45, significantly below today's trading price of $68.
📉 Recent insider transactions show a net selling trend with 75 recent deals tilting toward sales.
⏳ The next major catalyst is the August 5, 2026 FDA decision on mRNA-1010 approval.
🔬 Upcoming Phase 3 readouts for norovirus, intismeran in melanoma, and propionic acidemia are being watched.
🏦 Jefferies raised its price target to $53 while maintaining a Hold rating on the stock.
Bullish Signals
Shares surged 14% to new 52-week high of $69.29.
FDA unanimously endorsed flu vaccine mFlusiva for adults 50+.
Q1 2026 revenue jumped 264% YoY to $389 million.
Company reaffirmed up to 10% revenue growth guidance for 2026.
Stock gained 45% this month while peers lagged behind.
Risk Factors
Analyst target $43.45 is well below current price of $68.
Stock trades at forward P/E of 23x on uncertain earnings.
Recent insider net selling trend with 75 recent sales deals.
Leerink target near $24 and Morgan Stanley near $33.
Pfizer revenue fell 59% to $232 million in Q1 2026.
Consensus cautious with 16 Hold ratings against Buys and Sells.
Bullish Signals
Moderna shares surged 14% to hit a new 52-week high of $69.29, significantly outperforming peers Merck and Pfizer.
The FDA advisory committee unanimously endorsed Moderna's flu vaccine mFlusiva for adults 50 and older.
Q1 2026 revenue jumped 264% year-over-year to $389 million, beating consensus estimates by 65%.
Moderna reaffirmed guidance for up to 10% revenue growth in 2026 based on its recent 10-Q filing.
The company is advancing a diverse pipeline including T-cell engagers, an in-vivo CAR-T program, and a personalized cancer vaccine.
Moderna stock has gained 45% over the past month while Merck added only 7% and Pfizer fell 6%.
Year-to-date performance shows Moderna up 130% against Merck's 21% gain and Pfizer's 3% decline.
Jefferies analyst raised its price target to $53, signaling continued interest in the company's potential.
Risk Factors
The consensus analyst price target is $43.45, which is well below the current trading price of $68.
Moderna stock trades at a forward P/E ratio of 23x on still-uncertain forward earnings.
Recent insider transactions show a net selling trend with 75 recent deals tilting toward sales.
Leerink has a price target near $24 and Morgan Stanley near $33, indicating the stock is running ahead of Street positioning.
Pfizer's Comirnaty revenue fell 59% to $232 million in Q1 2026, underscoring reliance on non-COVID portfolios.
The sell-side consensus remains cautious with 16 Hold ratings against a smaller cluster of Buys and Sells.
Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month, reflecting strong momentum as investors pivot away from post-COVID concerns toward next-generation flu and oncology franchises. This regulatory milestone supports the company's Biologics License Application ahead of the August 5, 2026 PDUFA deadline.
Despite the positive catalysts, Moderna continues to report significant financial losses with quarterly revenue of $389M and a net loss of $1.34B for the quarter. Gross margins remain low at 22.6%, and EBITDA is negative $1.28B, indicating heavy ongoing R&D and operating expenditures. However, the company maintains a robust balance sheet with $5.2B in cash and short-term investments against total liabilities of $4.08B, providing ample liquidity to fund its expansion plans and restructuring efforts.
Management announced a strategic restructuring to support three commercial franchises across vaccines, oncology, and rare diseases, aiming for multiple launches between 2027 and 2028. Concurrently, Moderna is expanding its European footprint by investing in German manufacturing sites, including facilities previously operated by BioNTech. Analysts like Jefferies maintain a Hold rating with a $45 price target, noting that meaningful flu revenues are expected to ramp up starting in 2027, potentially reaching $750M in U.S. sales by 2030.
The stock's recent performance is attributed to the intersection of regulatory approval signals, corporate restructuring, and aggressive capacity build-out. Upcoming events include Moderna's Investor Science Day on June 25, 2026, where the company plans to showcase new programs leveraging mRNA technology combined with AI and robotics. Traders are closely monitoring these developments as the narrative shifts toward diversification beyond its COVID legacy.
📈 Moderna stock rose 6.21% to $63.08 on positive regulatory news.
✅ FDA voted unanimously for mRNA-1010 flu vaccine in adults 50+.
💰 Revenue hit $389M quarterly with $5.2B cash against $4.08B liabilities.
🔄 Restructuring supports vaccines, oncology, and rare disease launches by 2027–2028.
🇩🇪 Company invests in German manufacturing sites to expand European footprint.
📈 Moderna stock jumped 6.21% on Tuesday, June 23, 2026, rising from a low of $58.70 to close near $63.08 following positive regulatory and corporate news.
✅ The FDA advisory committee voted unanimously (9-0) that the mRNA-1010/mFLUSIVA flu vaccine has a favorable benefit-risk profile for adults aged 50–64 and 65+.
📅 This regulatory vote supports the Biologics License Application ahead of the August 5, 2026 PDUFA deadline for full approval in the U.S.
💰 Moderna reported quarterly revenue of $389M with trailing revenue of $1.94B, though it posted a net loss of $1.34B and EBITDA of -$1.28B.
🛡️ The company holds a strong balance sheet with $5.2B in cash, equivalents, and short-term investments against total liabilities of $4.08B.
🔄 Management announced a restructuring to support three commercial franchises preparing for launches in vaccines, oncology, and rare diseases in 2027–2028.
🇩🇪 Moderna plans to invest in German manufacturing sites, including facilities previously operated by BioNTech, to expand its European footprint.
📉 Analyst Jefferies reiterated a Hold rating with a $45 price target, estimating U.S. flu and combo sales could reach roughly $750M by 2030.
🔬 The upcoming June 25, 2026 Investor Science Day will feature new programs combining mRNA technology with AI and robotics for flu, oncology, and rare disease.
📊 Gross margins stand at 22.6% while EBIT margins are -140%, reflecting heavy R&D and operating spend despite the strengthening stock chart.
Bullish Signals
FDA voted 9-0 to support Moderna's flu vaccine, reducing regulatory risk.
Stock surged 34% from $47 to $63, showing strong investor confidence.
Company holds $5.2B cash against $4.08B liabilities for ample liquidity.
New three-franchise model signals strategic shift beyond the COVID one-hit-wonder.
German manufacturing expansion builds independent global capacity for future vaccines.
Risk Factors
Quarterly net income loss of -$1.34B.
Gross margins low at 22.6%.
EBIT margins negative at -140%.
Free cash flow loss of -$692M.
Bullish Signals
The FDA advisory committee voted unanimously (9-0) to support Moderna's mRNA-1010/mFLUSIVA flu vaccine, significantly reducing regulatory risk for the upcoming PDUFA deadline.
Moderna's stock price surged over 34% in less than a month, climbing from $47 to $63, indicating strong investor confidence in the company's strategic pivot.
The company possesses a substantial cash cushion of $5.2B against $4.08B in total liabilities, providing ample liquidity to fund restructuring and expansion without immediate distress.
Management's announcement of a new three-franchise operating model signals a clear strategic shift away from being a one-hit-wonder post-COVID company.
Expansion into German manufacturing sites demonstrates a commitment to building independent global capacity ahead of a broader product wave in vaccines and oncology.
Risk Factors
Moderna continues to operate at a significant loss with quarterly net income from continuing operations at -$1.34B and EBITDA of -$1.28B.
Gross margins are low at 22.6% and EBIT margins are steeply negative at -140%, reflecting heavy ongoing R&D and operating expenditures that pressure profitability.
Free cash flow remains negative at approximately -$692M for the quarter, indicating continued high burn rates despite strong cash reserves.
Moderna, Inc. (MRNA) is a biotechnology company that transitioned from a platform-stage entity to a commercial vaccine producer following the global success of its COVID-19 vaccine. The company leverages messenger RNA technology to direct cells in producing proteins for immune responses or addressing disease biology across infectious diseases, oncology, and rare genetic conditions.
The article provides a technical and fundamental snapshot of MRNA as of June 19, 2026. Analyst sentiment is currently mixed with 64% of analysts rating the stock as a Hold, while insider selling has been the primary negative factor over the last 90 days, with net sales of approximately $6.2M.
Despite the insider selling, technical indicators present a strongly bullish outlook. The stock price trades above both the 50-day and 200-day moving averages, supported by positive MACD momentum and a bullish Relative Strength Index (RSI). No meaningful insider purchases were recorded during the recent period.
🧬 Moderna develops mRNA medicines for infectious diseases, oncology, and rare disorders.
📉 64% of analysts rate the stock as a Hold.
💸 Insiders net sold $6.2M in stock over the last 90 days.
Moderna Inc.'s mRNA-based influenza vaccine has received a recommendation for approval from an external advisory committee of the US Food and Drug Administration (FDA). This development marks a significant positive milestone for the biotechnology company, which has faced scrutiny regarding this specific product line at the regulatory agency.
The vote represents a notable shift in FDA stance, suggesting a reversal of previous controversial decisions made under prior leadership. The article highlights that similar reversals are occurring across other drug approvals, citing UniQure NV's Huntington's disease gene therapy as a recent example where the FDA quickly moved from recommending new trials to allowing approval based on existing data.
While this advisory committee vote is not the final regulatory decision, it serves as a major victory for Moderna and indicates a more favorable environment for its mRNA technology platform moving forward. The outcome underscores the company's ability to navigate regulatory hurdles after facing significant challenges with its flu vaccine candidate.
📈 FDA advisory committee recommends Moderna mRNA flu vaccine.
🔄 FDA reverses prior controversial decisions under previous leadership.
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had previously rejected the application due to concerns about trial design, specifically the lack of a preferred higher-dose control arm for the elderly population.
The company successfully amended its application to address these initial concerns, leading to a favorable tone in the latest briefing documents ahead of an independent advisory panel meeting scheduled for Thursday. The panel will vote on whether mFlusiva's benefits outweigh risks for adults 50 and older, with a final FDA decision expected by August 5. If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States.
Despite some noted limitations, such as the vaccine being studied during only one flu season and the exclusion of immunocompromised or very frail older adults from trials, Moderna has agreed to conduct an additional study in the 65-plus age group if approval is granted for that specific population. Analyst Andrew Tsai from Jefferies views the assessment positively, projecting combined U.S. sales of $750 million for flu and COVID-flu combo vaccines by 2030.
Beyond the flu vaccine milestone, Moderna is gaining momentum with recent EU approval for mCOMBRIAX, its first-of-its-kind flu-plus-COVID combination vaccine globally. The company also appointed Ester Banque as Chief Commercial Officer to lead upcoming product launches. Investors are increasingly optimistic about a multi-product future, with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.
📈 Moderna stock rises after FDA documents support mFlusiva for adults 65+.
🔄 FDA reverses rejection following Moderna's trial design amendment for older adults.
🗓️ Advisory panel votes on mFlusiva; final decision expected by August 5.
💉 Approval would make mFlusiva the first mRNA seasonal flu vaccine in US.
⚠️ FDA notes study limitations including single-season data and excluded frail patients.
📈 Moderna stock surges for a fifth straight day after FDA staff reviewers publish briefing documents suggesting mFlusiva flu shot data supports effectiveness in adults 65 and older.
🔄 The FDA reversed its initial rejection of the flu vaccine application after Moderna agreed to amend its trial design regarding the control arm for patients 65 and over.
🗓️ An independent advisory panel will vote on mFlusiva benefits versus risks for adults 50 and older, with a final FDA decision expected by August 5.
💉 If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States.
📊 Jefferies analyst Andrew Tsai projects $750 million in combined U.S. flu and COVID-flu combo vaccine sales by 2030.
⚠️ FDA staff noted limitations including study during only one flu season and exclusion of immunocompromised or very frail older adults from trials.
🔬 Moderna agreed to run an additional study in the 65-plus age group if approval is granted for that population.
🌍 The company recently received EU approval for mCOMBRIAX, its flu-plus-COVID combination vaccine, marking the first of its kind globally.
👩💼 Moderna appointed Ester Banque as new Chief Commercial Officer to lead upcoming product launches globally.
🚀 Investors are optimistic about a multi-product future with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.
Bullish Signals
FDA documents suggest favorable review of mFlusiva flu vaccine.
Moderna reversed FDA rejection after amending trial design.
mFlusiva would be first mRNA-based seasonal flu vaccine in US.
Jefferies projects $750 million combined sales by 2030.
EU approved mCOMBRIAX, first global flu-plus-COVID combo vaccine.
Ester Banque appointed Chief Commercial Officer for launches.
Pivotal cancer and rare disease data expected in 2026.
Risk Factors
Limited to one flu season study.
Excluded immunocompromised and frail older adults.
FDA notes trial design and population limits.
Bullish Signals
Moderna stock has gained meaningfully over five trading sessions following the publication of FDA briefing documents that suggest a favorable review of its mFlusiva flu vaccine.
The FDA reversed its initial rejection of the flu vaccine application after Moderna amended its trial design, signaling a positive shift in regulatory stance.
Approval of mFlusiva would establish it as the first mRNA-based seasonal flu vaccine in the United States, creating a unique market position.
Analyst Andrew Tsai from Jefferies projects $750 million in combined U.S. sales for flu and COVID-flu combo vaccines by 2030.
Moderna recently secured EU approval for mCOMBRIAX, becoming the first company globally to receive approval for a flu-plus-COVID combination vaccine.
The appointment of Ester Banque as Chief Commercial Officer strengthens the company's leadership team for upcoming global product launches.
Future pivotal data readouts for cancer therapy Intismeran and rare disease programs are expected in 2026, suggesting a robust pipeline beyond vaccines.
Risk Factors
The mFlusiva vaccine has only been studied during one flu season, which may limit the generalizability of its effectiveness data.
Immunocompromised and very frail older adults were excluded from the trials for mFlusiva, leaving efficacy in these high-risk groups unproven.
The FDA briefing documents explicitly note limitations regarding the trial design and patient population included in the current data.
Moderna (MRNA) shares surged 9% today, extending a remarkable 94% gain year-to-date to trade near $57. This performance significantly outpaces peers Pfizer (PFE), which is up 4%, and Novavax (NVAX), which is up 41%. The rally is driven by corporate restructuring rather than new clinical data, as the company reorganizes its leadership to prepare for a major wave of product launches scheduled for 2027 and 2028.
The restructuring involves expanding President Stephen Hoge's role to oversee R&D, manufacturing, and commercial operations across three franchises, signaling a shift toward commercial scale. This operational backbone aligns with plans to launch up to three products by 2027-2028, including a flu-plus-COVID combination vaccine (mCOMBRIAX), a seasonal flu vaccine, and a norovirus vaccine. The company recently received EU approval for mCOMBRIAX and faces a key PDUFA decision on its seasonal flu candidate, mRNA-1010, on August 5.
Despite the strong stock performance, Moderna faces headwinds including a recent $878 million non-recurring litigation charge related to an Arbutus/Genevant patent settlement, which widened its Q1 2026 GAAP loss to $1.34 billion. Analyst sentiment remains cautious with an average one-year price target of $37 and a consensus 'Reduce' rating. The stock is still down 74% from its pandemic-era highs, framing the current rally as a rebound rather than a return to previous peaks.
Key upcoming events include an FDA advisory committee vote on June 18 regarding mFlusiva for adults 50 and older. A constructive readout could further support the stock, while a mixed verdict might test whether the 94% YTD gain is fully priced in. Investors are advised to monitor whether MRNA holds the $50 support level through these critical regulatory milestones before making position adjustments.
📈 Moderna stock rose 9%, extending a 94% year-to-date gain.
✅ EU approved mCOMBRIAX, the world's first flu-plus-COVID vaccine.
⚖️ Q1 2026 GAAP loss widened to $1.34 billion due to charges.
📉 Wall Street holds a 'Reduce' rating with a $37 price target.
🔍 FDA advisory vote on mFlusiva scheduled for June 18.
📈 Moderna stock jumped 9% today, extending a 94% year-to-date gain and outperforming peers Pfizer (+4%) and Novavax (+41%).
🏗️ The company announced a leadership restructuring to prepare for up to three product launches by 2027-2028, including flu-plus-COVID and norovirus vaccines.
✅ EU approval was granted for mCOMBRIAX, the world's first flu-plus-COVID combination vaccine, reinforcing the commercialization narrative.
📅 A critical PDUFA decision for the seasonal flu candidate mRNA-1010 is scheduled for August 5.
⚖️ Q1 2026 included an $878 million non-recurring litigation charge tied to the Arbutus/Genevant patent settlement.
📉 Wall Street maintains a cautious outlook with an average one-year price target of $37 and a consensus 'Reduce' rating.
🔍 An FDA advisory committee vote on mFlusiva for adults 50+ is scheduled for June 18, serving as a key near-term catalyst.
📊 Moderna's Q1 2026 GAAP loss widened to $1.34 billion due to the litigation charge and declining revenue from Comirnaty (-59%) and Paxlovid (-63%).
Bullish Signals
Moderna stock up 94% YTD, beating rivals.
Leadership shift targets commercial scale by 2027-2028.
EU approved mCOMBRIAX; mRNA-1010 PDUFA Aug 5.
Pipeline diversifies with flu-COVID combo and norovirus vaccines.
Comirnaty revenue down 59%; Paxlovid down 63% YoY.
Widened GAAP loss of $1.34 billion in Q1 2026.
Analysts rate 'Reduce' with average price target of $37.
Stock down 74% from pandemic-era peak highs.
Bullish Signals
Moderna stock has delivered a remarkable 94% return year-to-date, significantly outperforming major vaccine competitors Pfizer and Novavax.
The leadership restructuring signals a strategic shift toward commercial scale, preparing the company for multiple product launches in 2027-2028.
Regulatory momentum is strong with recent EU approval for mCOMBRIAX and an upcoming PDUFA decision for mRNA-1010 on August 5.
The pipeline includes diverse candidates such as a flu-plus-COVID combo vaccine, seasonal flu vaccine, and norovirus vaccine, diversifying future revenue streams.
Risk Factors
Moderna recorded a $878 million non-recurring litigation charge in Q1 2026 related to the Arbutus/Genevant patent settlement.
Revenue from key products is declining, with Comirnaty down 59% and Paxlovid down 63% year-over-year in Q1 2026.
The company reported a widened GAAP loss of $1.34 billion for the first quarter of 2026.
Analyst consensus remains cautious with an average one-year price target of $37 and a 'Reduce' rating.
The stock is still down 74% from its pandemic-era peaks, indicating significant downside from historical highs.
Moderna has launched Moderna Direct, a new direct-to-healthcare ordering platform powered by FFF Enterprises' proprietary BioSupply® ecommerce technology. This strategic partnership allows Moderna to bypass traditional distribution channels and offer its customers a customized, branded experience for accessing its product portfolio. The launch represents a significant step forward in how Moderna supports its business customers, with the company citing momentum for future innovation and expanded self-service capabilities.
Robert Keith, FFF's senior vice president of customer experience and communication, highlighted the rapid implementation and scalable foundation built to enhance the customer interface. Matt Block, U.S. general manager at Moderna, praised FFF as a strong collaborator committed to delivering value to customers. The platform is designed to meet the needs of manufacturing partners and enable direct-to-healthcare business models, leveraging FFF's 38-year history as a specialty pharmaceutical distributor.
Patrick M. Schmidt, CEO of FFF Enterprises, expressed honor in offering this capability as part of their suite of services for pharmaceutical manufacturing and healthcare provider customers. The company notes its investment in best-in-class technologies and cybersecurity solutions to support nationwide commerce. This collaboration underscores the growing trend of manufacturers utilizing specialized distributors' technology platforms to streamline direct sales and improve customer experiences in the specialty pharmaceutical sector.
🚀 Moderna launches "Moderna Direct" platform for streamlined healthcare product access.
🤝 Solution powered by FFF Enterprises' proprietary BioSupply® e-commerce technology.
🎨 Customized branded experience enhances ordering process and customer innovation.
🔄 Enables direct-to-healthcare models bypassing traditional distribution channels.
📞 Contact Michelle Valenzuela at FFF for service inquiries.
🚀 Moderna has launched a new direct-to-customer platform called "Moderna Direct" to streamline product access for healthcare customers.
🤝 The platform is powered by FFF Enterprises, Inc., a specialty pharmaceutical distributor based in Temecula, California.
💻 The solution utilizes BioSupply®, which is FFF's proprietary e-commerce platform built on a scalable foundation.
🎨 The new site features a customized, Moderna-branded experience designed to enhance the ordering process for customers.
🗣️ Robert Keith, SVP of customer experience at FFF, stated that the collaboration allows them to build on a strong foundation to elevate the customer experience.
🚀 Matt Block, U.S. general manager at Moderna, described the launch as an important step forward in supporting their customers and driving future innovation.
🏢 FFF Enterprises has been operating since 1988 and is a privately held, multibillion-dollar healthcare technology company.
🔄 The new platform enables direct-to-healthcare business models that bypass traditional distribution channels for manufacturing partners.
🛡️ FFF's nationwide commerce network utilizes world-class technology and cybersecurity solutions to support its partners.
📞 For inquiries regarding the e-commerce services, interested parties should contact Michelle Valenzuela, VP of marketing & communications at FFF.
Bullish Signals
Moderna selected FFF Enterprises' BioSupply® platform for its new Direct site.
Launch supports customers and drives innovation in Moderna's direct business model.
FFF brings 38 years of growth with scalable, intuitive interface enhancements.
Moderna Direct offers streamlined access via a customized, branded experience.
Partnership leverages world-class tech, cybersecurity, and nationwide distribution networks.
Bullish Signals
Moderna has selected FFF Enterprises' proprietary BioSupply® ecommerce platform to power its new Moderna Direct site, enhancing the ordering experience for customers.
The launch represents an important step forward in supporting customers and creates momentum for future innovation within Moderna's direct business model.
FFF Enterprises brings 38 years of growth and a strong, scalable foundation to this collaboration, ensuring intuitive interface enhancements and expanded self-service capabilities.
Moderna Direct provides streamlined access to the product portfolio through a customized, Moderna-branded experience that bypasses traditional channels.
The partnership leverages world-class technology and cybersecurity solutions supported by a nationwide network of distribution and infusion pharmacy locations.
Risk Factors
No negative aspects or risks identified in the provided article; it is a positive press release announcing a new partnership and platform launch.
On May 21, 2026, Flagship Pioneering, LLC executed a matched exercise-and-sell transaction involving Moderna (MRNA) shares. The entity exercised stock options to acquire 9,263 shares at an exercise price of $19.15 per share. Immediately following the acquisition, Flagship Pioneering sold the exact same quantity of shares on the open market at an average price of $46.84 per share.
The transaction was conducted by entities associated with Moderna director Noubar Afeyan. Following the sale, Flagship Pioneering retained a small indirect holding of 3,924 shares. The filing details significant direct and indirect holdings held by Noubar Afeyan and related Flagship Ventures funds, totaling millions of shares, while noting that Afeyan disclaims full beneficial ownership of shares held by the Flagship entities except to the extent of his pecuniary interest.
This Form 4 filing reports a standard exercise-and-sell sequence where an insider entity converts vested options into cash by selling the underlying stock. The sale price of $46.84 represents a substantial premium over the $19.15 option strike price, indicating the shares were purchased at a discount relative to their market value at the time of the transaction.
📅 Flagship Pioneering exercised options for 9,263 Moderna shares on May 21, 2026.
💰 Shares were immediately sold at $46.84 per share for a net profit of $27.69.
👤 Noubar Afeyan controls entities holding over 2 million direct and 4.6 million indirect shares.
⚖️ Afeyan disclaims full beneficial ownership, retaining interest only via his pecuniary stake.
📅 On May 21, 2026, Flagship Pioneering exercised options for 9,263 Moderna shares at $19.15 per share.
💰 The same entity immediately sold those 9,263 shares on the open market at an average price of $46.84 per share.
👤 Noubar Afeyan is the ultimate control person of the reporting entities and holds over 2 million direct shares.
🏦 Related Flagship Ventures funds hold additional indirect stakes totaling approximately 4.6 million shares combined.
📉 The transaction resulted in a net profit per share of roughly $27.69 before fees due to the spread between exercise and sale prices.
⚖️ Afeyan disclaims full beneficial ownership of Flagship entity holdings, retaining interest only to the extent of his pecuniary stake.
Bullish Signals
Insider sold at $46.84 premium vs $19.15 strike.
Noubar Afeyan owns over 2.2 million shares directly.
Matched exercise-and-sell is neutral liquidity, not distress.
Risk Factors
Sale of 9,263 shares increases supply and may lower price.
Afeyan's limited disclosure reduces visibility into his total exposure.
Bullish Signals
The insider sold shares at a significant premium to the option strike price ($46.84 vs $19.15), suggesting confidence in the stock's value relative to the cost basis.
Noubar Afeyan maintains substantial direct ownership of over 2.2 million shares, indicating continued skin in the game despite the sale activity.
The matched exercise-and-sell transaction is a neutral liquidity event rather than a signal of distress or lack of conviction.
Risk Factors
The open-market sale of 9,263 shares increases immediate supply, which can exert short-term downward pressure on the stock price.
Afeyan's disclaimer of beneficial ownership for Flagship entity holdings limits transparency regarding his total economic exposure to the company.
The FDA scheduled a public advisory committee meeting for June 18 to review Moderna's experimental mRNA flu vaccine, Mflusiva, examining its safety and effectiveness before a potential approval later in August. This meeting follows an initial rejection of the application in February by former FDA vaccines chief Vinay Prasad, despite objections from agency career staff, after which the agency agreed to reconsider the product following discussions with the company. Approval could mark a significant milestone as Moderna's shot would be the first flu vaccine utilizing mRNA technology.
Moderna is seeking this new growth avenue as its stock has declined significantly from pandemic-era highs due to falling demand for its Spikevax COVID-19 vaccine. The proposed Mflusiva vaccine faces scrutiny because it utilizes mRNA technology, which has been criticized by Health and Human Services Secretary Robert F. Kennedy Jr., who currently oversees the FDA. The upcoming review aims to determine if the standalone flu shot can help reignite growth for the biopharmaceutical company after its reliance on pandemic-era vaccines wanes.
🩺 FDA reviews Moderna's experimental mRNA flu vaccine at a June 18 advisory meeting.
⏳ Approval is required before standalone distribution can begin in August.
🔄 The agency reverses a February rejection following earlier regulatory objections.
🧬 Mflusiva marks the first influenza vaccine developed using mRNA technology.
🩺 The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental flu vaccine, Mflusiva.
🔬 This gathering will feature independent scientific and public-health experts evaluating the vaccine's safety and effectiveness.
⏳ Moderna is awaiting regulatory approval to begin standalone distribution of this flu shot later this August.
🔄 The agency reversed a February rejection of Mflusiva after initial objections from then-acting FDA vaccines chief Vinay Prasad.
📉 Moderna's stock prices have dropped significantly due to declining demand for its pandemic-era Spikevax product.
🧬 Mflusiva will be the first influenza vaccine developed using mRNA technology, a format currently criticized by HHS Secretary Robert F. Kennedy Jr.
Bullish Signals
FDA meeting scheduled June 18 for Mflusiva review.
Agency pivoted from February rejection to convene scientific review.
Moderna positioned for standalone flu approval by late August.
Mflusiva would be the first mRNA flu vaccine.
Risk Factors
FDA rejected initial standalone flu shot application due to Vinay Prasad.
HHS Secretary RFK Jr. criticizes mRNA technology and oversees FDA.
Moderna stock dropped from pandemic highs amid falling Spikevax demand.
August regulatory approval critical; June 18 meeting could delay timeline.
Bullish Signals
The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental influenza vaccine, Mflusiva.
After an initial rejection in February due to objections from the vaccines chief, the agency pivoted and agreed to convene this scientific review.
Moderna is positioned to receive standalone flu shot approval later this August if the review is successful.
Mflusiva would be the first flu vaccine made with mRNA technology, offering a new technological platform for the company.
Risk Factors
Moderna's initial application for its standalone flu shot was rejected in February at the behest of Vinay Prasad, the FDA's vaccines chief, indicating significant regulatory hurdles ahead.
The proposed Mflusiva vaccine faces criticism from Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA and has publicly criticized mRNA technology.
Moderna's stock has already tumbled from pandemic-era highs due to falling demand for Spikevax, adding pressure before this new product launch.
The company is facing a critical dependency on regulatory approval later in August, with the upcoming June 18 advisory committee meeting being a potential bottleneck that could delay or jeopardize the timeline.
The article argues that while Moderna (MRNA) recently surged 63% year-to-date following a Q1 revenue triple, its long-term fundamentals remain weak. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, with management projecting only up to 10% growth for 2026 off this depressed base. Approximately 80% of Q1 2026 sales originated outside the U.S., and the company's franchise is still heavily reliant on a single COVID product.
Moderna faces significant financial headwinds, with year-end cash projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by the end of 2026. The company drew $600 million on a credit facility while Q1 GAAP net loss widened to $1.34 billion. There are no dividends or buybacks, and upcoming catalysts like the August 5, 2026 flu vaccine PDUFA and melanoma readouts are described as binary events rather than steady earnings drivers.
In contrast, the author recommends Gilead Sciences (GILD) as a superior long-term holding for retirement portfolios. Gilead is characterized as a cash-flow machine with an HIV franchise that grew 10% to $5.03 billion in Q1 2026, driven largely by Biktarvy which generated $3.36 billion alone. The company trades at a forward earnings multiple of 15 and offers a 2.46% dividend yield with a market cap near $162 billion.
Gilead provides real shareholder returns through a declared quarterly dividend payable June 29, 2026, and significant stock repurchases totaling $419 million in Q1 alone against a $6.0 billion buyback authorization. The company's headline EPS loss is attributed to roughly $11.5 billion in one-time IPR&D charges from recent acquisitions rather than operational issues. With a strong pipeline including four potential launches and five Phase 3 updates anticipated in 2026, Gilead can fund its growth from operating cash flow.
📉 Moderna 2025 revenue collapsed 40% to $1.94 billion.
💸 Moderna cash projected to fall to $4.5B–$5.0B by 2026.
📈 Gilead Q1 HIV revenue hit $5.03B driven by Biktarvy.
🛡️ Gilead's Biktarvy patent extended to April 2036.
📊 Gilead trades at 15x forward earnings vs Moderna's depressed base.
📉 Moderna's full-year 2025 revenue collapsed to $1.94 billion, representing a roughly 40% drop from the prior year.
💸 Moderna's year-end cash is projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by year-end 2026.
📈 Gilead Sciences generated Q1 2026 HIV franchise revenue of $5.03 billion, a 10% increase driven by Biktarvy sales of $3.36 billion.
💰 Gilead declared a quarterly dividend of $0.82 payable June 29, 2026, and repurchased $419 million of stock in Q1 alone.
🔬 Moderna's upcoming catalysts are binary events like the August 5, 2026 flu vaccine PDUFA rather than steady earnings drivers.
🛡️ Gilead's patent protection on Biktarvy was extended to April 2036, ensuring no major loss of exclusivity for a full decade.
📊 Gilead trades at a forward earnings multiple of 15 with a market cap near $162 billion compared to Moderna's depressed base.
🧬 Gilead's headline EPS loss guidance is an artifact of roughly $11.5 billion in one-time IPR&D charges from acquisitions like Arcellx and Ouro Medicines.
Bullish Signals
Q1 free cash flow hit $2.427 billion, up 237% YoY.
HIV franchise grew 10% to $5.03 billion in Q1 2026.
Offers 2.46% dividend yield and $6.0 billion buyback authorization.
Non-GAAP gross margin expanded 200 bps to 87.5%.
Strong pipeline with four launches and five Phase 3 updates in 2026.
Risk Factors
Single COVID product creates concentration risk outside U.S.
No dividend or buybacks while drawing on credit facility.
Upcoming catalysts are binary events with high uncertainty.
Gilead possesses a strong pipeline with up to four potential launches and five Phase 3 updates anticipated in 2026.
Moderna's recent stock surge is attributed to a prior year disaster rather than improved fundamentals, suggesting the bounce may be temporary.
Risk Factors
Moderna's entire franchise is effectively a single COVID product, creating concentration risk outside the U.S. market.
Moderna has no dividend and no buyback program while actively drawing on its credit facility to manage liquidity.
Moderna's upcoming catalysts are binary events with high uncertainty rather than predictable earnings drivers.
Gilead's headline EPS loss guidance is driven by roughly $11.5 billion in one-time IPR&D charges from acquisitions, which may impact reported profitability.
Investing.com reports that Moderna (MRNA) shares jumped 13% following news of a Hantavirus outbreak aboard the cruise ship MV Hondius, though research from Bernstein Global Research suggests this stock move may be short-lived. The localized outbreak infected roughly 10 passengers and crew with the Andes strain, which has shown human-to-human transmission unlike standard strains, resulting in three deaths. Bernstein maintained its Market-Perform rating with a price target of $45.00, implying 17% downside from May 8's closing price of $54.35. Analysts caution that the localized transmission makes a global pandemic unlikely, and while Moderna is technically capable of pivoting to Hantavirus countermeasures due to its scalable mRNA platform, these collaborations are currently in preclinical stages with no commercially approved vaccines for Hantavirus Cardio-Pulmonary Syndrome (HCPS). Developing such vaccines would require Phase 1 through Phase 3 trials costing over $500 million.
Reuters reports that Moderna exceeded Wall Street revenue estimates for the first quarter, driven by better-than-expected international COVID-19 vaccine sales. International revenue reached $311 million compared to $78 million in the U.S., helping first-quarter revenue more than triple to $389 million from a year earlier, surpassing the analyst estimate of nearly $228 million. Chief Financial Officer Jamey Mock noted the company is transitioning to a more balanced global revenue story and expressed hope that regulatory uncertainty under Health Secretary Robert F. Kennedy Jr. has diminished. The company secured an August 5 FDA decision date for its mRNA-based flu vaccine after resolving a previous dispute, with plans to expand into norovirus vaccines, individualized cancer vaccines with partner Merck, and treatments for rare metabolic disorders.
Moderna reiterated its 2026 revenue growth forecast of up to 10%, expecting roughly half of total revenue from the U.S., down from 62% last year. The company expects second-quarter revenue between $50 million and $100 million, evenly split between domestic and international markets, while posting a net loss per share of $3.40 versus an analyst estimate of $3.96. This loss included $2.22 per share in charges related to settling a patent dispute over lipid nanoparticle technology with Roivant Sciences' unit Genevant and Arbutus Biopharma. Additionally, German biotech company CureVac sued Moderna in Delaware federal court alleging that the COVID-19 vaccine Spikevax infringed on mRNA stabilizing patents, seeking royalties from sales. BioNTech, which acquired CureVac, also filed a separate patent lawsuit against Moderna in February regarding its next-generation mNEXSPIKE shot.
📈 Moderna shares surged 13% after Hantavirus outbreak news on cruise ship MV Hondius.
💰 Developing multi-strain vaccines requires $500M+ in trials with no immediate consumer rollout.
🏛️ Future revenue projected as steady government funding for state stockpiling rather than sales.
📊 Moderna beat Q1 estimates, posting $389M revenue vs $228M analyst expectations.
⚖️ CureVac sued Moderna over patent infringement regarding mRNA stabilization technology.
📈 Moderna shares surged 13% following news of a Hantavirus outbreak on cruise ship MV Hondius involving 10 infections and 3 deaths.
⚠️ Bernstein Global Research downplays pandemic risk, maintaining a Market-Perform rating with a $45 price target implying 17% downside from recent highs.
🦠 The lethal Andes strain of Hantavirus on the ship has demonstrated human-to-human transmission, unlike standard strains spread by rodent contact.
🧬 Moderna is well-positioned to pivot to Hantavirus countermeasures using its scalable mRNA platform with existing research partnerships.
💰 Developing a comprehensive multi-strain vaccine would require $500+ million in Phase 1-3 clinical trials with no immediate consumer rollout expected.
🏛️ Future commercial returns are projected as steady government funding for state stockpiling rather than mass market sales.
📊 Moderna beat first-quarter revenue estimates, posting $389 million compared to analysts' expectations of roughly $228 million.
🌍 International revenue drove growth to $311 million versus $78 million domestically as partnerships in the UK and Australia strengthened.
💼 CFO Jamey Mock stated the company aims for a balanced international vs. U.S. revenue story by 2026 amid shifting vaccine policies.
📅 FDA approval is expected for Moderna's mRNA-based flu vaccine on August 5 after resolving prior trial design disputes.
🎯 The company is expanding into new therapies with late-stage dates expected for norovirus vaccines, a cancer vaccine, and metabolic disorder treatments.
⚖️ RBC Capital notes full-year revenue will be weighted toward the back half, with an anticipated second-quarter range of $50 million to $100 million.
💸 Q4 net loss of $3.40 per share included $2.22 in charges from settling patent disputes over lipid nanoparticle technology.
⚔️ German biotech CureVac sued Moderna in Delaware federal court alleging Spikevax infringed on patents related to mRNA stabilization technology.
🏢 BioNTech, which acquired CureVac last year, also filed a separate lawsuit against Moderna regarding its next-generation mNEXSPIKE COVID-19 shot.
Bullish Signals
Shares surged 13% amid Hantavirus reports on MV Hondius.
Risk Factors
Bernstein cut target to $45, implying 17% downside from May 8 price.
Hantavirus stockpiling limits near-term commercial returns for current pipeline.
Multi-strain vaccine trials could cost over $500 million before gains.
U.S. policy changes under RFK Jr. introduce regulatory uncertainty.
Patent disputes incurred $2.22/share settlement charges and litigation risk.
Bullish Signals
Moderna Inc (NASDAQ:MRNA) shares rallied 13% over a multi-day period following reports of a localized Hantavirus outbreak aboard the cruise vessel MV Hondius.
Risk Factors
Bernstein analysts downplayed pandemic risk, noting Hantavirus outbreaks are highly localized and unlikely to mirror the COVID-19 trajectory, suggesting current market enthusiasm may be short-lived.
Bernstein reiterated a Market-Perform rating with a price target of $45.00, implying a 17% downside from Moderna's May 8 closing price of $54.35.
Any successful Hantavirus countermeasures would likely result in steady government funding for stockpiling rather than mass consumer rollout, limiting near-term commercial returns.
Development of a comprehensive multi-strain vaccine could require phase 1 through phase 3 clinical trials with estimated expenditures exceeding $500 million, creating significant financial risk before any commercial gains.
Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. have led to reduced vaccine use and reshaped the regulatory landscape for companies developing new shots, introducing uncertainty into the U.S. market.
Moderna expects 2026 revenue growth of up to 10%, but first-half 2025 revenue is weighted at only 15% compared to a much higher second half, indicating significant front-loaded volatility risk.
Q1 net loss per share was $3.40 versus analyst estimates of a loss of $3.96, though this included one-time charges that may impact underlying earnings visibility.
Moderna faced a patent dispute with Roivant Sciences and Arbutus Biopharma, incurring $2.22 per share in settlement charges related to lipid nanoparticle technology.
German biotech company CureVac sued Moderna in Delaware federal court alleging that the Spikevax COVID-19 vaccine infringed on mRNA technology patents, adding potential litigation risk and royalty exposure.
Moderna (NASDAQ:MRNA) was ranked number one on TIME's 2026 list of the World's Most Impactful Companies, a distinction based on the Upright Project's Net Impact Model which evaluates net-positive contributions across Society, Knowledge, Health, and Environment. The recognition highlights Moderna's status as a pioneer in mRNA technology and its commitment to delivering meaningful benefits for patients and society through innovative medicines addressing unmet needs in infectious diseases, oncology, and rare diseases.
In 2026, the company achieved a significant regulatory milestone with European approval for mCOMBRIAX, its fourth product and first combination vaccine targeting both flu and COVID. This expansion of its respiratory portfolio supports broader pandemic preparedness efforts. Additionally, Moderna deepened long-term strategic partnerships with the UK, Canada, and Australia to expand manufacturing capacity and minimize response times for future pandemics.
Beyond commercial products, Moderna highlighted its commitment to global health equity through its mRNA Access program, which has grown to include 35 institutions worldwide since its 2022 launch. The company also marked the fourth anniversary of its Charitable Foundation and published its fourth annual Impacting Human Health Report, reinforcing its focus on societal impact alongside scientific advancement.
🏆 Ranked #1 on TIME's 2026 World's Most Impactful Companies list.
💉 European approval granted in 2026 for mCOMBRIAX flu/COVID vaccine.
🤝 Expanded partnerships with UK, Canada, and Australia for pandemic readiness.
🔬 mRNA Access program now includes 35 global research institutions.
📅 Celebrated fourth anniversary of Charitable Foundation and released annual report.
🏆 Moderna ranked #1 on TIME's 2026 World's Most Impactful Companies list based on the Upright Project's Net Impact Model.
💉 European regulatory approval granted in 2026 for mCOMBRIAX, a flu plus COVID combination vaccine.
🤝 Strategic partnerships expanded with the UK, Canada, and Australia to boost pandemic preparedness and manufacturing capacity.
🔬 mRNA Access program now includes 35 institutions globally researching vaccines for emerging infectious diseases.
📅 Moderna celebrated the fourth anniversary of its Charitable Foundation and released its fourth annual Impacting Human Health Report.
🧬 CEO Stéphane Bancel emphasized the team's dedication to advancing mRNA science for patients and communities worldwide.
Bullish Signals
Moderna ranked #1 on TIME's 2026 list.
EU approved mCOMBRIAX flu/COVID single-shot vaccine.
Alliances with UK, Canada, Australia show confidence.
mRNA Access program grew to 35 institutions.
Bullish Signals
Moderna secured the top spot on TIME's prestigious 2026 list, validating its leadership in mRNA technology and societal impact.
The European approval of mCOMBRIAX expands Moderna's product portfolio with a novel single-shot combination vaccine for flu and COVID.
Strategic alliances with major nations like the UK, Canada, and Australia demonstrate strong government confidence in Moderna's pandemic readiness capabilities.
The growth of the mRNA Access program to 35 institutions showcases the company's success in fostering open scientific collaboration for neglected diseases.
Moderna faces significant commercial headwinds as mRNA vaccines struggle in post-pandemic markets, prompting a strong sell recommendation based on underperformance against traditional competitors. RSV and flu mRNA candidates are criticized for lower durability, higher side effects, and weak market uptake, resulting in program cuts and strategic pivots by the company. While combination therapies like mCOMBRIAX show regulatory progress, commercial success remains uncertain due to persistent consumer vaccine fatigue and lack of immediate financial viability in current indications.
The article highlights that personalized cancer vaccines, while potentially leveraging mRNA technology's speed advantages, face substantial hurdles including margin constraints, scalability issues, and regulatory complexities that limit their near-term financial upside for Moderna. The author, a Chemistry PhD with biotech investment experience, notes these challenges stem from the technology being viable primarily in pandemic-level scenarios rather than routine annual immunization markets where competition is intensifying from established protein-based vaccine makers.
The analysis concludes that without new breakthroughs or regulatory fast-tracking that overcomes current limitations regarding durability and adverse events, Moderna's revenue trajectory looks weaker than peers, particularly given the expiration of patent-protected revenue streams that once drove stock valuations. The investment thesis suggests investors should be cautious of capital allocation risks as management attempts to pivot from pandemic-era products to harder-to-develop treatments in a crowded therapeutic landscape without guaranteed commercial returns.
📉 mRNA vaccines struggle with lower durability, side effects, and weak post-pandemic market uptake.
✂️ Commercial setbacks force program cuts and a strategic pivot away from current vaccine portfolios.
⚠️ Analysts rate Moderna "Strong Sell" due to intense competition and uncertain financial upside.
🔬 Traditional competitors outperform in key segments, weakening Moderna's overall competitive position today.
📉 Moderna (MRNA) faces significant commercial setbacks as its mRNA vaccines underperform compared to traditional competitors in post-pandemic markets.
💉 RSV and flu mRNA vaccines are struggling due to lower durability, higher side effects, and weak market uptake.
✂️ These commercial challenges have led to program cuts and a need for strategic pivots within Moderna's vaccine portfolio.
🤝 Combination mRNA vaccines such as mCOMBRIAX show regulatory progress, but commercial success remains uncertain due to ongoing vaccine fatigue.
🧬 Personalized cancer vaccines utilizing mRNA technology may benefit from speed, yet face hurdles in margins, scalability, and regulation that limit financial upside.
📄 The analysis is based on the premise that mRNA vaccines may only be viable in scenarios similar to the recent COVID-19 pandemic conditions.
🏆 Traditional competitors are outperforming Moderna in current market segments, weakening its competitive position in key therapeutic areas.
📊 Previous investment coverage from 2024 highlighted risks regarding the uncertain future of mRNA vaccines in a post-pandemic world.
🔬 The author identifies as a Chemistry PhD and scientist with expertise in biotech data to inform their investment thesis.
⚠️ Analysts recommend a "Strong Sell" rating for Moderna stock given these negative commercial trends and uncertainties.
📅 Article published on May 12, 2026, reflecting current market conditions and sentiment as of that date.
🛡️ Standard disclosures indicate the author holds no position in Moderna stock and receives no compensation beyond Seeking Alpha affiliation.
⚖️ Seeking Alpha's standard disclaimer notes that past performance does not guarantee future results and that this is not formal investment advice.
Bullish Signals
Combination mRNA vaccines like mCOMBRIAX have achieved regulatory progress, signaling potential pathway for future development.
Personalized cancer vaccines leverage the inherent speed of mRNA technology, offering a distinct advantage for R&D efficiency.
Risk Factors
MRNA underperforms in post-pandemic markets.
RSV & flu mRNA vaccines have durability issues.
mCOMBRIAX faces commercial uncertainty.
Personalized cancer vaccines face scalability hurdles.
Bullish Signals
Combination mRNA vaccines like mCOMBRIAX have achieved regulatory progress, signaling potential pathway for future development.
Personalized cancer vaccines leverage the inherent speed of mRNA technology, offering a distinct advantage for R&D efficiency.
Risk Factors
Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets.
RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and strategic pivots.
Combination mRNA vaccines like mCOMBRIAX offer regulatory progress but commercial success remains uncertain amid persistent vaccine fatigue.
Personalized cancer vaccines may leverage mRNA speed but face margin, scalability, and regulatory hurdles, limiting their financial upside for MRNA.
Moderna (MRNA) shares recently surged, gaining up to 22% over two days, driven by investor speculation regarding a hantavirus outbreak linked to an Atlantic cruise ship. The incident resulted in three fatalities and sparked international headlines, triggering market memory from the 2020 pandemic era despite the World Health Organization noting that human-to-human transmission remains rare.
Moderna is positioned as a primary beneficiary due to its existing early-stage research into hantavirus vaccines and collaborations with the U.S. Army and Korea University. However, the company explicitly describes these efforts as ongoing, and there is currently no approved vaccine for hantavirus available on the market.
Analysts warn of a significant valuation disconnect between the stock's rally and its fundamental reality. While Moderna's stock price has risen sharply over the past 12 months, a localized outbreak is unlikely to generate the multibillion-dollar revenue streams seen during the COVID-19 era. The article suggests that unless clinical trial timelines accelerate significantly, this rally may prove fleeting as investors buy the headline rather than the substance.
📈 Moderna stock surged 22% after hantavirus cruise ship deaths.
🔬 Company holds early-stage vaccine research with U.S. Army and Korea.
⚠️ No approved hantavirus vaccine exists; Moderna's efforts remain ongoing.
💰 Rally driven by headlines, not comparable multibillion-dollar revenue potential.
📈 Moderna stock surged up to 22% in two days following news of a deadly hantavirus cluster on an Atlantic cruise ship.
🦠 The outbreak involved three fatalities and sparked international headlines, causing investors to recall the market dynamics of the 2020 pandemic.
🔬 Moderna holds early-stage research collaborations with the U.S. Army and Korea University for a hantavirus vaccine.
⚠️ There is currently no approved vaccine for hantavirus, and Moderna describes its efforts as 'early-stage and ongoing'.
💰 Investors are buying the headline, but the localized outbreak is unlikely to generate multibillion-dollar revenue streams comparable to COVID-19.
📉 The article warns that without significant acceleration in clinical trial timelines, the current rally may be fleeting.
📊 Moderna's stock has been trading below its pandemic peak of over $350 for nearly two years prior to this recent surge.
Bullish Signals
Natural first pick for hantavirus due to strong research.
Credible mRNA platform with unique early-stage data vs. peers.
Risk Factors
No product available; efforts are early-stage and ongoing.
Stock price rose sharply without immediate revenue potential.
Localized outbreaks unlikely to match COVID-19 era revenue.
Rally may be fleeting if trials do not accelerate.
Bullish Signals
Moderna is identified as the 'natural first place to look' for hantavirus plays due to its long-standing research and existing collaborations with the U.S. Army and Korea University.
The company possesses a credible mRNA platform specifically positioned for this rodent-borne pathogen, distinguishing it from competitors without such early-stage data.
Risk Factors
Moderna explicitly describes its hantavirus vaccine efforts as 'early-stage and ongoing,' meaning no product is currently available for sale.
The article highlights a 'classic valuation disconnect' where the stock price has risen sharply despite the lack of immediate revenue potential from this specific threat.
Analysts caution that a localized outbreak will likely not generate the massive revenue streams seen during the COVID-19 era, limiting the fundamental upside.
The rally is described as potentially 'fleeting' if clinical trial timelines do not accelerate significantly to meet investor expectations.
Simply Wall St analyzes Moderna (MRNA), noting a recent surge with a 51.4% year-to-date return and a current price of $46.71. The article questions whether the market has overvalued the stock, citing a DCF model that projects significant future cash outflows until 2030, resulting in an intrinsic value of roughly $3.90 per share.
This valuation suggests Moderna is significantly overvalued by approximately 1,097% based on discounted cash flow analysis. However, the stock's Price-to-Sales ratio of 8.33x is comparable to industry and peer averages, though it exceeds the platform's proprietary 'Fair Ratio' of 1.56x, indicating potential expense relative to growth expectations.
The article presents two contrasting investment narratives for Moderna. An optimistic view sees a strong balance sheet and a transition period following COVID-19 revenue pullbacks, implying a fair value near $175. Conversely, a cautious narrative views current positives as fully priced in, flags risks like competition and pricing pressure, and suggests the stock is fairly valued at roughly $46.10.
📉 DCF model projects negative cash flows through 2027 with intrinsic value of $3.90.
💰 Moderna trades at 8.33x sales, exceeding the calculated fair ratio of 1.56x.
📈 Stock delivered 91.2% return last year despite weaker long-term historical performance.
🧠 Optimistic view cites strong balance sheet and pipeline with potential fair value of $175.
⚠️ Cautious view notes risks around vaccine demand and regulatory scrutiny near current price.
📉 DCF Analysis: A two-stage free cash flow model projects negative cash flows through 2027, implying an intrinsic value of $3.90 versus the current price of $46.71.
💰 Valuation Metrics: Moderna trades at a Price-to-Sales ratio of 8.33x, which aligns with industry peers but exceeds the platform's calculated Fair Ratio of 1.56x.
📈 Recent Performance: The stock has delivered a 91.2% return over the last year and a 51.4% return year-to-date despite weaker long-term historical returns.
🧠 Optimistic Narrative: One investor story frames recent weakness as an overreaction, highlighting a strong balance sheet and a broad mRNA pipeline with a potential fair value of $175.
⚠️ Cautious Narrative: Another perspective views current positives as reflected in the price, citing risks around vaccine demand and regulatory scrutiny with a consensus fair value near $46.10.
🏦 Financial Health: The company is noted for having low debt and a balance sheet that some analysts view as trading below book value.
Bullish Signals
91.2% return over last year.
51.4% gain year-to-date.
Strong balance sheet with low debt.
Significant mRNA pipeline in trials.
P/S ratio of 8.33x vs 10.82x industry avg.
Risk Factors
DCF projects $3.2B outflows in 2026 and $1.5B in 2027.
Stock overvalued by 1,097% per DCF intrinsic value calculation.
Current P/S ratio of 8.33x exceeds fair multiple of 1.56x.
Revenue risks from vaccine demand fluctuations and competition.
Analyst targets near current price imply limited immediate upside.
Bullish Signals
Moderna has delivered exceptional recent performance with a 91.2% return over the last year and a 51.4% gain year-to-date.
The company maintains a strong balance sheet characterized by low debt levels.
A significant portion of the mRNA pipeline is currently in trials, suggesting future growth potential as earlier investments mature.
The stock trades below book value according to one optimistic valuation narrative, indicating assets may be undervalued relative to price.
Moderna's Price-to-Sales ratio of 8.33x is competitive and close to the Biotechs industry average of 10.82x.
Risk Factors
The Discounted Cash Flow model projects substantial negative free cash flows, estimating outflows of $3.2 billion in 2026 and $1.5 billion in 2027.
A DCF-based intrinsic value calculation suggests the stock is overvalued by approximately 1,097% compared to current market prices.
The proprietary Fair Ratio analysis indicates the stock is expensive relative to a calculated fair multiple of 1.56x versus the current 8.33x P/S ratio.
Risks include potential instability in revenue due to vaccine demand fluctuations, intense competition, and regulatory scrutiny.
Analyst consensus price targets sit close to the current share price, implying limited immediate upside from a neutral valuation perspective.
Moderna (MRNA) shares rose 4.6% following a post-earnings repricing driven by stronger international vaccine deliveries and reiterated growth frameworks for 2026. The company reported first-quarter 2026 revenue of $389 million, with approximately 80% derived from international markets under long-term partnership agreements. Management highlighted a plan to return to sales growth, targeting up to 10% revenue expansion while reducing GAAP operating expenses in the current year.
The financial results included a first-quarter GAAP net loss of roughly $1.3 billion, or $(3.40) per share, largely due to a non-recurring litigation settlement charge of $0.9 billion recorded in cost of sales and royalties. Excluding this one-time charge, the company emphasized its operational progress and regulatory milestones, including EU approvals for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX, as well as the initiation of a Phase 3 trial for intismeran in high-risk stage 1 NSCLC.
Analyst sentiment remains mixed but active, with several firms lifting price targets following the quarterly release. The median analyst price target stands at $34.0, though individual targets vary significantly, ranging from $30.0 by Jefferies to a bullish $69.0 by Piper Sandler. Institutional ownership saw notable shifts in Q4 2025, with major funds like FMR LLC and Capital World Investors adding substantial positions, while others like UBS reduced theirs.
📈 Moderna shares rose 4.6% on strong Q1 results and pipeline news.
💰 Q1 revenue hit $389M, with 80% from international markets.
⚖️ GAAP loss of $1.3B included a $0.9B litigation settlement charge.
✅ EU approved mNEXSPIKE and flu+COVID combo vaccine mCOMBRIAX.
🔬 Phase 3 trial for intismeran in NSCLC officially initiated.
📈 Moderna shares gained 4.6% as investors reacted positively to Q1 results and pipeline updates.
💰 Q1 2026 revenue reached $389 million, with 80% coming from international markets.
⚖️ GAAP net loss was $1.3 billion due to a $0.9 billion non-recurring litigation settlement charge.
📈 Management reiterated a 2026 plan for up to 10% revenue growth and reduced operating expenses.
✅ EU regulatory approvals were secured for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX.
🔬 A Phase 3 trial for intismeran in high-risk stage 1 NSCLC has officially initiated.
📅 The U.S. PDUFA date for the seasonal flu vaccine candidate is set for August 5, 2026.
🏦 FMR LLC added over 15.7 million shares to its portfolio in Q4 2025.
📉 Insider selling was prominent, with President Stephen Hoge offloading 160,009 shares.
🎯 Analyst price targets range widely from $30.0 to $69.0, with a median of $34.0.
Bullish Signals
Q1 revenue hit $389M with 80% from international sales.
Management targets reduced GAAP expenses in 2026.
EU approved mNEXSPIKE and flu+COVID combo vaccine mCOMBRIAX.
Phase 3 intismeran trial launched for NSCLC oncology.
Analysts raised price targets after quarterly earnings release.
Major investors FMR LLC and Capital World increased holdings.
Risk Factors
Q1 GAAP net loss of $1.3 billion.
High insider selling by President and CLO.
Net institutional outflow: 319 vs 301 investors.
Two firms issued 'Underperform' ratings.
Bullish Signals
Moderna reported Q1 revenue of $389 million, demonstrating strong international demand that accounts for roughly 80% of total sales.
Management has committed to reducing GAAP operating expenses in 2026, excluding the one-time litigation charge, signaling improved operational efficiency.
The company achieved significant regulatory milestones with EU approvals for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX.
Initiation of the Phase 3 intismeran trial in high-risk stage 1 NSCLC marks a critical step toward potential oncology revenue diversification.
Several analysts have lifted price targets following the quarterly release, indicating renewed investor interest in the stock's trajectory.
Major institutional investors like FMR LLC and Capital World Investors significantly increased their holdings in Q4 2025.
Risk Factors
The company recorded a substantial GAAP net loss of $1.3 billion in Q1, primarily driven by a $0.9 billion non-recurring litigation settlement charge.
Insider selling activity has been high over the past six months, with President Stephen Hoge and Chief Legal Officer Shannon Thyme Klinger both executing sales.
Institutional ownership is mixed, with 319 investors decreasing their positions in the most recent quarter compared to 301 adding shares.
Analyst ratings are divided, with two firms issuing 'Underperform' ratings from Leerink Partners and B of A Securities.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)